Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

The Vanda Miss Joaquim was born and bred in Singapore in 1893, in the garden of a woman named Agnes Joaquim, an Armenian horticulturist who lived in Tanjong Pagar.

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti ...

The Vanda coerulea, also known as blue orchid or Blue Vanda, was first identified in 1847. The flower grows in cooler regions, from forests in the Himalayan regions to South-east Asia. Its juice ...

FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...

(Reuters) -Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda's stock following ...

Cycle is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda Board’s continued refusal to engage following the receipt of multiple premium proposals ...

Oct 14 (Reuters) - Vanda Pharmaceuticals (VNDA.O), opens new tab on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after ...

Despite failing its primary endpoint in gastroparesis, Vanda is still pushing for regulatory approval for tradipitant, facing regulatory hurdles. Despite receiving two acquisition offers with a ...

Buying the right camera, lens, accessory or software to suit your photography is really important. Our product reviews offer independent views with hands-on opinion and honest verdicts aimed to ...

WASHINGTON, July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2024.